In terms of both clinical data and sales, drug makers Celltrion and Pfizer have seen recent gains for their infliximab biosimilar, CT-P13 (Inflectra, Remsima).
In terms of both clinical data and sales, drug makers Celltrion and Pfizer have seen recent gains for their infliximab biosimilar, CT-P13 (Inflectra, Remsima).
At the 25th United European Gastroenterology Week in Barcelona
, Spain, drug maker Celltrion presented
from a phase 1, open-label study of a subcutaneous form of CT-P13 in healthy volunteers. The study, designed to evaluate the safety and pharmacokinetics of the infliximab biosimilar, found that subcutaneous administration of the drug was feasible in terms of bioavailability and safety, and the researchers suggested that a subcutaneous administration could present a more convenient and accessible option for patients receiving infliximab.
In addition to these results, Pfizer presented data from a 54-week, phase 3
that supported the long-term effectiveness of CT-P13 in patients with Crohn’s disease, and that supported switching from the reference product to the biosimilar.
A poster
presented at the same meeting reported on a biosimilar switching project carried out in the Rheumatology and Gastroenterology departments in the Princess Alexandra Hospital in the United Kingdom. Patients who had been receiving reference infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and irritable bowel disease were switched to biosimilar CT-P13. Patients were seen at 6 to 8 weeks post-switch to review their response to the biosimilar. The poster’s authors report that 13 patients responded well to the biosimilar, while 2 patients had to switch back to the originator biologic due to a loss of disease control. The main impact of the switch, the authors state, is the financial benefit and cost savings produced by switching.
CT-P13 also demonstrated gains in terms of third-quarter sales. Celltrion and Pfizer’s biosimilar was responsible for $112 million in worldwide sales over the quarter, with $34 million of those sales in the United States,
to Pfizer’s quarterly report. Meanwhile, Johnson and Johnson, makers of the reference infliximab (Remicade),
slowing sales of its innovator drug; Remicade experienced a 1.3% drop in US sales, and an 8.2% drop in worldwide sales. The reference infliximab still commanded $1.6 billion of the global infliximab market, however.
While CT-P13's sales may not yet have achieved blockbuster status, performance of the drug in the United States is reason for optimism, according to some analysts. While US biosimilar uptake is typically slower than EU uptake, “Remsima sales went up [47.8%] in the [United States] this quarter, compared to the previous quarter. In Europe, it rose [42.2%] year-on-year. From 2018, it will see strong growth in earnest,” Shin Jae-hoon, analyst at EBEST Investment and Securities,
Korea Biomedical Review.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.